Valuation: Inhalation Sciences Sweden AB

Market Cap 9.47M 992K 862K 803K 738K 1.4M 94.39M 1.41M 3.7M 47.19M 3.73M 3.64M 156M P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 6.64M 696K 604K 563K 517K 979K 66.18M 989K 2.6M 33.08M 2.61M 2.56M 110M EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
94.25%
Yield 2024 *
-
Yield 2025 -
1 day-1.07%
1 week-15.91%
Current month+2.78%
1 month-21.61%
3 months-24.49%
6 months-46.22%
Current year-95.74%
1 week 0.18
Extreme 0.18
0.21
1 month 0.18
Extreme 0.18
0.25
Current year 0.17
Extreme 0.172
0.58
1 year 0.17
Extreme 0.172
0.58
3 years 0.17
Extreme 0.172
4.99
5 years 0.17
Extreme 0.172
11.3
10 years 0.17
Extreme 0.172
15.48
Manager TitleAgeSince
Chief Executive Officer - 16/09/2019
Chief Tech/Sci/R&D Officer - 01/01/2005
Corporate Officer/Principal - 02/06/2025
Director TitleAgeSince
Director/Board Member - 01/01/2005
Director/Board Member - 01/09/2022
Director/Board Member - 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%-15.91%-95.74%-93.62% 992K
-1.62%-2.02%+21.04%+2.94% 209B
-1.38%-2.15%-1.36%-23.54% 137B
-1.90%+1.79%-23.81%+19.06% 130B
+1.36%+6.58%-54.03%-3.21% 71.14B
+0.88%+7.07%+11.87%+12.63% 51.59B
+0.01%+4.08%-14.64%-19.92% 49.99B
-0.43%-0.95%+21.21%+10.21% 39.31B
+5.69%+3.17%+38.69%+36.63% 38.89B
+0.76%+9.59%-0.54%-7.43% 31.74B
Average +0.66%+1.56%-9.73%-6.63% 75.85B
Weighted average by Cap. +0.41%+1.53%-0.70%+1.17%

Financials

2024 2025
Net sales 11.05M 1.16M 1M 937K 861K 1.63M 110M 1.65M 4.32M 55.03M 4.35M 4.25M 182M 3.04M 319K 277K 258K 237K 448K 30.31M 453K 1.19M 15.15M 1.2M 1.17M 50.2M
Net income -5.15M -539K -468K -437K -401K -758K -51.3M -767K -2.01M -25.64M -2.03M -1.98M -84.96M -10.16M -1.06M -924K -862K -792K -1.5M -101M -1.51M -3.97M -50.62M -4M -3.91M -168M
Net Debt -4M -419K -364K -340K -312K -590K -39.89M -596K -1.56M -19.94M -1.57M -1.54M -66.08M -2.83M -297K -258K -240K -221K -417K -28.21M -422K -1.11M -14.1M -1.11M -1.09M -46.73M
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
5
Date Price Change Volume
04/08/26 SEK 0.1850 -1.07% 87
03/08/26 SEK 0.1870 +3.89% 19,325
31/07/26 SEK 0.1800 -16.67% 370,147
29/07/26 SEK 0.2160 -1.82% 248,550
28/07/26 SEK 0.2200 -3.08% 1,027

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISAB Stock